Virtual Library

Start Your Search

Hildy Grossman



Author of

  • +

    P1.02 - Advocacy (Not CME Accredited Session) (ID 934)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.02-03 - The Role of Lung Cancer Advocacy Organizations in Biomarker Testing (ID 12003)

      16:45 - 18:00  |  Author(s): Hildy Grossman

      • Abstract
      • Slides

      Background

      In the past 10 years, major advances have been made in our understanding and treatment of lung cancer. Lung cancer is now recognized as not just a single disease, but rather comprises many subtypes, each with unique molecular characteristics or biomarkers. Most new treatment options developed and under development for non-small cell lung cancer (NSCLC) target specific biomarkers, and these targeted therapies are improving outcomes in patients with the applicable biomarker. Despite this progress, biomarker testing is often viewed as an optional service by both patients and their healthcare team.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      In March 2018, a roundtable was convened consisting of executives from lung cancer advocacy organizations and key opinion leaders in the lung cancer field to discuss trends in biomarker testing for patients with lung cancer. The main objective of the roundtable was to develop an action plan to increase awareness of biomarker testing to ensure all lung cancer patients receive the most effective treatment.

      4c3880bb027f159e801041b1021e88e8 Result

      Several barriers were identified that may contribute to suboptimal biomarker testing including lack of patient and physician awareness, inadequate tissue sampling, slow turn-around time, limited availability in some community settings, and health policy issues surrounding access, cost, and reimbursement. Patient advocacy groups are well positioned to address the lack of patient awareness with education campaigns. However, the lack of consistent language to describe biomarker testing among organizations is a barrier. To address this issue, advocacy groups need to align on common terminology and messaging with regard to biomarkers. Two potential approaches to achieve this goal include: 1) collaboration to develop joint educational material or 2) collaboration to develop a shared consensus statement including best practices and common core items or ‘building blocks’ for use by each organization to develop their own materials. As a first step, consistent messaging with regard to the Who, What, When, Where, Why, and How of biomarker testing are needed. Understanding gaps in physician knowledge regarding biomarker testing and development of initiatives to address these gaps are also warranted.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Additional patient and physician education are needed to establish biomarker testing as part of standard of care in patients with advanced-stage NSCLC, with the ultimate goal being that the patient has a full biomarker panel available (or at least tests in progress) at their first appointment with an oncologist. A unified effort from lung cancer advocacy organizations, healthcare providers, and industry partners is needed to achieve this goal.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.